<SEC-DOCUMENT>0001628280-25-038855.txt : 20250807
<SEC-HEADER>0001628280-25-038855.hdr.sgml : 20250807
<ACCEPTANCE-DATETIME>20250807160257
ACCESSION NUMBER:		0001628280-25-038855
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250807
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250807
DATE AS OF CHANGE:		20250807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		251193794

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sgmo-20250807.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:743e3d1d-5209-4147-9f9e-f186c95e6166,g:edce170c-c226-4361-93ed-553981498f19,d:239daec4b18b46edbcb67b08cbe53161-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20250807</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20250807.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-07</xbrli:startDate><xbrli:endDate>2025-08-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i239daec4b18b46edbcb67b08cbe53161_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;7, 2025</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.574%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30171</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>ID Number)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">501 Canal Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Richmond</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94804</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">510</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">970-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:6.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:6.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.681%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.574%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;7, 2025, Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;) issued a press release announcing its financial results for the quarter ended June 30, 2025 (the &#8220;Press Release&#8221;).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:12.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.693%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991080725.htm">Press Release regarding financial results dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991080725.htm"> August 7,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991080725.htm"> 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.306%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 7, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT B. WILLOUGHBY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Scott B. Willoughby</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit-991080725.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i91129f0e69bb4291a9719dfd4144fb30_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:432pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logo.gif" src="logo.gif" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECOND QUARTER 2025 FINANCIAL RESULTS</font></div><div><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First clinical site initiated for Phase 1&#47;2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticipated in late 2026.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held productive meeting with Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study ahead of anticipated Clinical Trial Application (CTA) submission.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RICHMOND, California, August 7, 2025 - </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (Nasdaq&#58; SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2025 financial results.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;I&#8217;m proud of the progress achieved across our pipeline this quarter. The announcement of positive topline results from our registrational STAAR study in Fabry disease represented a significant step forward on our path towards commercialization for this important program,&#8221; said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. &#8220;This quarter we also became a clinical-stage neurology company, with the initiation of our first clinical site in the Phase 1&#47;2 STAND study in chronic neuropathic pain. We are excited to soon dose the first patient in this study and look forward to sharing clinical data by the end of 2026.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Highlights</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Updates</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raised approximately $21 million in net proceeds from an underwritten registered equity offering. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fabry Disease</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced positive topline results from the registrational Phase 1&#47;2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following a single dose of isaralgagene civaparvovec, a positive mean annualized eGFR slope of 1.965 mL&#47;min&#47;1.73m2&#47;year (95% confidence interval (CI)&#58; -0.153, 4.083) at 52-weeks was observed across all 32 dosed patients in the study, which the FDA has agreed will serve as an intermediate clinical endpoint under the Accelerated Approval pathway. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Furthermore, a mean annualized eGFR slope at Week 104 of 1.747 mL&#47;min&#47;1.73m2&#47;year (95% CI&#58; -0.106, 3.601) was observed for the 19 patients who have achieved 104-weeks of follow-up.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Key secondary endpoints in the study were also positive. Elevated expression of alpha-galactosidase A (&#945;-Gal A) activity was maintained for up to 4.5 years for the longest treated patient. Plasma lyso-Gb3 levels remained generally stable following Enzyme Replacement Therapy (ERT) withdrawal. A stabilization in cardiac endpoints was also observed, including cardiac function, morphological and biomarker data in the 32 patients with 52 weeks of follow-up.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patients demonstrated a range of other clinical benefits, including improvements in disease severity reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adjusted score and statistically and clinically significant improvements in the short form-36 (SF-36) quality of life scores at week 52 compared to baseline. Statistically significant improvements in the gastrointestinal symptoms rating scale (GSRS) compared to baseline were also observed. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Furthermore, following a single administration of isaralgagene civaparvovec, additional clinical benefits were observed in some patients, such as the reduction or elimination in pain medication usage and the resumption of sweating, that has enabled these patients to perform physical tasks and exercise. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile in the study, without the requirement for preconditioning. The majority of adverse events were grade 1-2 in nature.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We believe these data support the potential for isaralgagene civaparvovec to be a one-time, durable treatment for Fabry disease that can improve patient outcomes and will form the basis for an anticipated Biologics License Application (BLA) submission under the Accelerated Approval pathway as early as the first quarter of 2026.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sangamo plans to present additional clinical data at the 15</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> International Congress of Inborn Errors of Metabolism (ICIEM2025), September 2-6, 2025 in Kyoto, Japan. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sangamo continues to engage with the FDA ahead of the planned BLA submission for isaralgagene civaparvovec, and continues to engage in business development negotiations for a potential Fabry commercialization agreement.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Core Neurology Pipeline</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chronic Neuropathic Pain &#8211; ST-503</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Nine clinical sites selected to date for the Phase 1&#47;2 STAND study evaluating ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First clinical site has been initiated and patient identification is in progress.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expect to dose first patient in the fall of 2025, with preliminary proof of efficacy data anticipated in Q4 2026. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Plan to present updated nonclinical data at the 9</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> International Congress on Neuropathic Pain, taking place September&#160;4-6, 2025 in Berlin, Germany.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prion Disease &#8211; ST-506</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CTA-enabling activities continue to advance for ST-506, an investigational epigenetic regulator for the treatment of prion disease, leveraging STAC-BBB. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Held productive meeting with the MHRA, including alignment on nonclinical safety studies and clinical study design.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented in the prestigious Presidential Symposium at the 28</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> American Society of Gene &#38; Cell Therapy (ASGCT) Annual Meeting to showcase the potent combination of epigenetic regulation and capsid delivery technology for the treatment of prion disease in animal models, including a profound survival extension observed in disease mouse models.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed ST-506 dose range finding study and advancing preparations for good laboratory practice (GLP) toxicology study. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A CTA submission for ST-506 is expected as early as mid-2026.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter 2025 Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated net loss for the second quarter ended June 30, 2025 was $20.0 million, or $0.08 per share, compared to a net loss of $36.1 million, or $0.18 per share, for the same period in 2024.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the second quarter ended June 30, 2025 were $18.3 million, compared to $0.3 million for the same period in 2024.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $18.0 million in revenues was primarily attributable to our receipt of an upfront license payment under our capsid license agreement with Eli Lilly and Company.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAAP and Non-GAAP Operating Expenses</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(In millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75.5&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses on a GAAP basis for the second quarter ended June 30, 2025 were $36.2 million, compared to $37.4 million for the same period in 2024. Non-GAAP operating expenses, which exclude impairment charges, depreciation and amortization, and stock-based compensation expense, for the second quarter ended June 30, 2025 were $33.0 million, compared to $31.9 million for the same period in 2024.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total operating expenses on a GAAP basis was primarily driven by cost reductions resulting from the strategic realignment of the business, which included a lower headcount due to the restructuring of operations and corresponding reductions in workforce, lower impairment charges recorded in the current year, contract termination costs recorded in 2024 relating to a manufacturing-related supplier arrangement, and a decrease in facilities and infrastructure costs. These decreases were partially offset by an increase in clinical and manufacturing expenses due to BLA readiness activities for our Fabry disease program.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents as of June 30, 2025 were $38.3 million, compared to cash and cash equivalents of $41.9 million as of December 31, 2024. Based on our current operating plan, we believe that our cash and cash equivalents as of June 30, 2025, together with the proceeds from sales of common stock under our at-the-market offering program since June 30, 2025, will be sufficient to fund our planned operations into the fourth quarter of 2025. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Guidance for 2025 Reiterated</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On a GAAP basis, we continue to expect total operating expenses in the range of approximately $135 million to $155 million in 2025, which includes estimated non-cash stock-based compensation expense, and depreciation and amortization.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $7 million, and estimated depreciation and amortization of approximately $3 million, in the range of approximately $125 million to $145 million in 2025, consistent with 2024. This reflects our intention to operate a lean neurology-focused business and to continue advancing isaralgagene civaparvovec towards a potential BLA submission, while continuing to engage in business development negotiations for a potential Fabry commercialization agreement.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Upcoming Events</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo plans to participate in the following events&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Conferences</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cantor Global Healthcare Conference 2025, September 3-5, 2025</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wells Fargo Healthcare Conference, September 3-5, 2025</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Access links for available webcasts for investor conferences will be available on the Sangamo website in the Investors and Media section under </font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Events</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Available materials will be found on the Sangamo website after the event under </font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Presentations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Sangamo management team will hold a corporate call to further discuss program and financial updates on Thursday, August 7, at 4&#58;30pm Eastern Time. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Participants should register for, and access, the call using </font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">this link</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. While not required, it is recommended you join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">An updated corporate presentation is available in the Investors and Media section under </font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Presentations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The link to access the live webcast can also be found on the Sangamo website in the Investors and Media section under </font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Events</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. A replay will be available following the conference call, accessible at the same link.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About Sangamo Therapeutics</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo&#8217;s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit</font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> www.sangamo.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and connect with us on</font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> LinkedIn </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and</font><font style="color:#0a2299;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> X</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to&#58; Sangamo&#8217;s cash runway and ability to continue to operate as a going concern&#59; the therapeutic and commercial potential and value of Sangamo&#8217;s product candidates, including the durability of therapeutic effects, the therapeutic and commercial potential and value of technologies used by Sangamo in its product candidates, including the potential for isaralgagene civaparvovec to be a one-time, durable treatment for Fabry disease that can improve patient outcomes&#59; expectations concerning regulatory approval and commercialization of isaralgagene civaparvovec, including the potential for isaralgagene civaparvovec to qualify for the FDA&#8217;s Accelerated Approval program, the adequacy of data generated in the Phase 1&#47;2 STAAR study to support FDA approval, and plans for a potential BLA submission for isaralgagene civaparvovec and the timing thereof&#59; Sangamo&#8217;s plans and ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including its plans to secure a commercialization partner for its Fabry disease program&#59; the anticipated plans and timelines for conducting, and presenting clinical data from, clinical trials&#59; the advancement of Sangamo&#8217;s preclinical neurology programs, including plans related to initiation of patient dosing for ST-503 and announcement of preliminary proof of efficacy data, and the anticipated prion disease CTA submission and announcement of related preliminary clinical data, and in each case the timing thereof&#59; Sangamo&#8217;s estimates regarding the sufficiency of its cash resources and its expenses, capital requirements and need for substantial additional financing&#59; Sangamo&#8217;s 2025 financial guidance&#59; plans to participate in industry and investor conferences&#59; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo&#8217;s lack of capital resources and need for substantial additional funding to execute its operating plan and to continue to operate as a going concern, including the risk that Sangamo will be unable to obtain substantial additional funding on acceptable terms or at all or collaboration partners necessary to advance its preclinical and clinical programs, in particular for its Fabry disease program and to otherwise operate as a going concern, in which case Sangamo may be required to cease operations entirely, liquidate all or a portion of its assets and&#47;or seek protection under the U.S. Bankruptcy Code&#59; the potential for collaborators and licensees to breach or terminate their agreements with Sangamo&#59; the potential for Sangamo to fail to realize its expected benefits from its collaboration and license agreements&#59; the uncertain and costly research and development process, including the risk that preclinical results may not be indicative of results in any future clinical trials&#59; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflicts, tariffs, geopolitical instability, inflation and fluctuations in interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators, including the initiation and operation of clinical trials&#59; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates&#59; the uncertain timing and unpredictable nature of clinical trial results, including risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1&#47;2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, including that the 104-week data from such study will not verify the clinical benefit of isaralgagene civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT&#59; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities&#59; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any registrational trial of Sangamo&#8217;s product candidates&#59; the potential for technological developments that obviate technologies used by Sangamo&#59; Sangamo&#8217;s reliance on collaborators and its potential inability to secure additional collaborations, and Sangamo&#8217;s ability to achieve expected future operating results.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All forward-looking statements about Sangamo&#8217;s future plans and expectations, including Sangamo&#8217;s financial guidance and development plans for its product candidates, are subject to Sangamo&#8217;s ability to secure adequate additional funding. There can be no assurance that Sangamo and its collaborators will be able to develop commercially viable products or that Sangamo will earn any milestone or royalty payments under its collaboration agreements. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo&#8217;s Securities and Exchange Commission, or SEC, filings and reports, including in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and subsequent filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP operating expenses, which excludes depreciation and amortization, stock-based compensation expense and impairment of long-lived assets from GAAP operating expenses. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded depreciation and amortization, and stock-based compensation expense because they are non-cash expenses that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented, and we have excluded impairment of long-lived assets to facilitate a more meaningful evaluation of our current operating performance and comparisons to our operating performance in other periods. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.</font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contacts</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Investor Relations</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Louise Wilkie&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;sangamo.com </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Media Inquiries</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Melinda Hutcheon</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;sangamo.com </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-more-</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited&#59; in thousands, except per share amounts)</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Data&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,306&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,743&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27,084&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,223&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53,090&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">60,114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,077&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,045&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,136&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,812&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,172&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,161&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,440&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72,226&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">89,447&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(17,855)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(37,084)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(47,483)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(88,610)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,649)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,698&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19,959)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(36,054)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(50,437)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(85,045)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-13.51pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(19,986)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(36,128)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(50,583)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(85,217)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-13.51pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-13.51pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">256,950&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">203,946&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">238,711&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">194,049&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Selected Balance Sheet Data&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">38,344&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41,918&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97,558&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101,635&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,602&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22,770&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sgmo-20250807.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:743e3d1d-5209-4147-9f9e-f186c95e6166,g:edce170c-c226-4361-93ed-553981498f19-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20250807" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20250807">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20250807_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20250807_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.sangamo.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sgmo-20250807_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:743e3d1d-5209-4147-9f9e-f186c95e6166,g:edce170c-c226-4361-93ed-553981498f19-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_4d71369b-4851-4645-bb4e-c01cf6c3d4ce_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8391b1de-1f73-46e6-8449-50ddb8404035_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5f55d698-ca42-44ed-a6c0-2915add86d49_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_438501fd-2d60-4434-ac73-5a132b515325_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f347ab09-9c83-4227-be03-74b96f5c0e73_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_697509d8-5684-420d-bb7f-84bed6a41232_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_88473c26-0b09-4064-8aa7-b51b71b566dc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2c102187-7da1-4f19-900d-087ca4fa735e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_318fdced-233e-42ff-a29d-e95527f1a5a1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4e0f968e-502f-40ef-8ee5-2469eb49822d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_39f3a522-82fb-469a-9d93-261d090a335c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f747dd7d-638c-48ee-a231-d0ea7cec5ab0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5cb13899-d00a-4574-adc7-ddd30684d008_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4225ce01-de4e-4305-8b33-d25816ef2b64_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5cd8901b-67b7-411d-86cd-bc17f436fe64_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_166a4248-2429-4380-bab1-873604b5dcc7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1466def7-ff1f-420f-bc36-8382e981cd98_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c3dcb86c-1e65-4638-b50f-fede14d59817_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_09fdcf90-2c43-4fed-a04e-9c404bb6fd94_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_70812422-b816-4f36-b640-4f63df0ee7aa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c8c143c1-f0cc-4b54-b51c-ce3d3131915e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_80037195-7e4a-493b-aef5-e61800c836a9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a6524ecf-7777-4a0b-b827-34b552dfd93a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sgmo-20250807_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:743e3d1d-5209-4147-9f9e-f186c95e6166,g:edce170c-c226-4361-93ed-553981498f19-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CoverPage" xlink:type="simple" xlink:href="sgmo-20250807.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_25503e82-b302-4780-8961-d343ae8e194e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_DocumentType_25503e82-b302-4780-8961-d343ae8e194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3747d737-7772-418d-8220-62f9ab2ef526" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_DocumentPeriodEndDate_3747d737-7772-418d-8220-62f9ab2ef526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_90bb5452-91af-4da6-91aa-43b35773fd13" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityRegistrantName_90bb5452-91af-4da6-91aa-43b35773fd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7e926115-f762-4616-aee1-ea8a18ad12c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7e926115-f762-4616-aee1-ea8a18ad12c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b241f93b-3d85-493a-a7a5-a6ee9d99993d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityFileNumber_b241f93b-3d85-493a-a7a5-a6ee9d99993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_40855b0d-c84b-4acb-b47f-08cb3bdec4d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityTaxIdentificationNumber_40855b0d-c84b-4acb-b47f-08cb3bdec4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3ad7f305-c9d6-4312-9680-c2fccd133065" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityAddressAddressLine1_3ad7f305-c9d6-4312-9680-c2fccd133065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_391127ff-2b86-4beb-9bba-6441579a263d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityAddressCityOrTown_391127ff-2b86-4beb-9bba-6441579a263d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4a7a27f3-cb7c-4cee-a0ba-56b2774a92e2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityAddressStateOrProvince_4a7a27f3-cb7c-4cee-a0ba-56b2774a92e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8868bb84-2daf-4116-9425-e77c1f1e17bc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityAddressPostalZipCode_8868bb84-2daf-4116-9425-e77c1f1e17bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_39dd27c0-9b54-4a25-ba06-9aaa12ae491b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_CityAreaCode_39dd27c0-9b54-4a25-ba06-9aaa12ae491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9dd99308-6c54-46f2-8a80-e731f9673e3c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_LocalPhoneNumber_9dd99308-6c54-46f2-8a80-e731f9673e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d483ed8f-8d9e-4745-8f07-df0e3a7bead5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_WrittenCommunications_d483ed8f-8d9e-4745-8f07-df0e3a7bead5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_aa8a086b-38c3-480c-9360-bf6323afdf79" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_SolicitingMaterial_aa8a086b-38c3-480c-9360-bf6323afdf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_137a77db-cb9b-425c-9f05-2b9c2317fe87" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_PreCommencementTenderOffer_137a77db-cb9b-425c-9f05-2b9c2317fe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4c3d3e3f-1a4c-4488-9550-7642ad3c8dfd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4c3d3e3f-1a4c-4488-9550-7642ad3c8dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d20d41ac-6b0b-4ad2-800a-2b2176340008" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_Security12bTitle_d20d41ac-6b0b-4ad2-800a-2b2176340008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d1dbe0a5-c4c9-41ea-afe9-1c58fbc40da5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_TradingSymbol_d1dbe0a5-c4c9-41ea-afe9-1c58fbc40da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4c0673c5-1fe1-4971-a8fb-0f259b3d0aad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_SecurityExchangeName_4c0673c5-1fe1-4971-a8fb-0f259b3d0aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_028ab4d5-9c78-4e60-9063-fd26d77540c5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityEmergingGrowthCompany_028ab4d5-9c78-4e60-9063-fd26d77540c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8ed08d1a-e771-4fd4-83d7-2c07a82e5b94" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_EntityCentralIndexKey_8ed08d1a-e771-4fd4-83d7-2c07a82e5b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_962ea481-54d9-45d7-8f8a-c0f1056d21f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7de2332e-cf36-45eb-bc1e-4eed465950ec" xlink:to="loc_dei_AmendmentFlag_962ea481-54d9-45d7-8f8a-c0f1056d21f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.gif
M1TE&.#EA@ -# 7   "'_"TY%5%-#05!%,BXP P$!   A^00      "P
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MQ"$' ;-E-79&/E157&_%98\ENQCT!2N% -OJI%]7 A]P.N3<.%XD-D($ 7F
M!C'GO3D0 AU@5!ET WZ73.'+VMM9 3APT#A&,P=61I8EO3 41-.BP4NV/!ZF
MPA>1K$(BIY>* ]\\P$/D#SJ34 PE1EG&+0#\.VFS@@<*#M8R207#Q?;&,"AI
M)).:5U5IAE7* %&#0M:R3=C=R:]T4S<C9G%8#Q*CG42I7^ =Q^*\V0LT.4F&
M.2N2?8!6#X+6VV*#9#@P< >^@P 5D#^4,\-5!U.Y8T#;PV^VE;O;Y \=$ )S
MJ$F2ZZEW \A0A$[YQCT%\$B313@"A#O\XM"JHC&QIMA$^J>;@C)Z$\Y YV\)
MY4*- V!$==KU_3K44VN28TD28-><J53_G*%? A/C&R5/-W61C4,Y0B.)W=C$
MVH;7'6&\O>O")WTZF_P]9$1 C[1H:AYG5F55IO1C8/0O*]4-&H"T)5!,<6S9
MI$8[VS(MPLJQ # /G88!E#1_Z]3B#P!2;!0$4 .^6:Q-599%I715C81/\C6M
M$%#%%:.)./Z"/N+#\YDN:? !<>PWFXRNM4M3"K1,$TQC2<9!J5("<]M,.77?
M'@#:Q4N7@7DJ2Q=RQK1*I;0]<"9(K%,]8&C5]VU4U"(%VW#<A\@ *N-.U"Y?
MD=9]-&ESD[Y%L0,#5E!R#>@/LU5<M<LZ9V15OQ4._/#78F/H#B@TSRF+T!7$
MIR,P!&135L-H_^0S7FZV/0#F-?O'+^GW@BDIH#Z(>H)2EYFY=/^[@*]$16Q%
M5-G313=EW^G%8 %30=H" ^  [Q6X5Y_N%P*8 Y(#>XMC:/5D,UM#>Q_ *F5<
M$H'IP[&IW!M!)MD8*VMP!3/<#?Z"3E(46S9#\>+#;YKE\!/\+VC3G.YM-FC^
M?"U.V6A48R.084J2*2JE=T!Z[@=$.=:6\_=\PP)&.(7#51S^4Q$%,(Z&02.@
MP<'6O2#*$7ZXB9-<ZB-P=4.-,XDT.'T]U-9$.PB O=BL-FN "0B#KJFD9#^Y
MK$=9-'-I>U"#TE16WA'T?$Y/,&1E1N1&D4(NNS+C4,F<01H [8!6;_]B0W:'
M@T,,]04:Q'_:EP+FE%4-7CU1KSKWC$L^5  34']"CNS/MTAJCF5_[@],&I=Y
MQ7O%( 758I&5C4!"+E@_-#N L^XS0^?\\P$(ZRFMZ-61=S^@4@(: #TS=3-;
M)EPWL #W[46J\R_^\%7S'3T.N&1R2LGM&AGB:I#SD C6%4]H%4%TMG\ D8,!
M P %B10$D +A0H8-'3XL2% !08(0+5[$R' @Q1Q7;D3X<N-&2)$W"A0P:?(+
M2'XKO_ ;^3*F2)(/;MC\DC-F! <01EQ9,^\#@I G"9P,1^!!A +AFL8<H:%B
M"@4*"GX8071FT0(3O$Z ^<4!C&TP.HP-F7;_Y%J8_%JR5!MWK=H"#^KF=,!-
M @0V%0$0L9I1\$(%WHAX ^!M(( 2;"!8@0%#9%("!+Z$NV%Y[F:YG&_"?/ %
M!H(1(V"(F#=O#0P',E>^A>WRQH@*%"U6#&PU,  * !C08; F!"8$B;YH#>F4
M<H&TS N$1;G2)LKI-FV*?)#]!@(($#2D&:@!P5JE-YE^:5K9)@:?X'H7#,QF
M?$Z0(,,]4$_SN#^BS8\JE>T+FS!C+JR8,,LI) 1(8Z.$C0I3[+<K()#@!A@>
M@ &:DYB+ #2CZ@(I)+=:&G$MD3 H[0H'-_)ML(L.2LP@W@@2(1'3$."'@'#"
MB6 IYM;"23\1YPK1_\3.Z!,P')@DL&"$#P9ZCZ'=7*2R2BNOQ#++AQ K2"$
MK&*@! ]T<DFZD'#"*2WI6D- *@:B1&A*+36:2+>+[)P3(0;DY*T@"BCX (+Y
M?LRN+I1NFHLD,A55T[,SE^HQ._ZX@8$-'&@R2CV0G#OJNC9;U&V@*RBMCTRC
M)B!@ LQ".VZ^- W]PK*VRFP-)$<]BS2"&[J!P0H)HLHASSNK4HPQ!M@(H308
M+K!0.0)ZM*Q(,F]==*3["+SI. @Z"&$>':!9*QP!;Q"7.O32&B%8W!CR$L_=
M#J(H3!Q&&+<UG>ZK+%6GR*4).R#_I>ZF B+%3ZD'1O IA-JNT.H!IS2+M?^
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ME!:7&!@$/#MTVB8I((W;JH=$^  VJ(#P&YPQ.KX608PID9.^/$B(X#$^VRH
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M@*_I( Y:O!ZYOAI2LJ9 BN:2K,P8&-0Q)T;+0;0TJB)CO&KTH1O(1H880\R
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M_"D/0A0&&PE*4&$(8>=6#/*!*,I+1U.,5.> $S&0[ >5*;PI3G.*FC"^1H4
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M0%S/Q[F=H(3=4;"!_,R133S>CT#&60S6U6CD2AFF0:K%)^6(/V GT9!DFWI
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M8-/IC<(;$7BXF#+A%!0K+O7KIT9U@@3]7JM9 5LV;-BSY;5N?>0;0X5'KR"
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M(BZW@RQ"4 378 3RB"8Z3KXJ!S CH#+^[CK(YRC@R,)VT.=N( <7+Q0!( C
MC;?(:"LX)1AGCY^$* 5,X)/@<960#!Y!;\B0\'?FT5A^!P1.P"+J<F9D8A;3
M*RJ0Z"L@H&SRY#6M_W1=H*,O'M U?:,G2D"H$F.C+,L_4.;!8("]1"KC$D<2
M$\,_591$YNQ"P^<H\*PC0D*WP$I1HJHCMF_P--"[*F<F&\4!+BLL7"KA%NK\
MS&@\H<IT)NHHX*>FON_0C",DBDU+L^9"'K&LXF(D+F8WH0(KHV=H/L,9,4U
MWT(PPA++\*9.T((R!/4I[% J$&#7,B0#%34Q0#1Q .52[V2!5J]^UN0$ 25(
MA'*L&.@OIV[/.'0+=88D;Y4!@J!I2$1,,",W@U%Q7%+#3. (B&6P6D-XFI#(
MV.TV2,\VNF %CN!YC$3'N&5!ADHYJ*A-ZP(#+ !]KC1?UP6"[&7N%O)0"_]N
M9+2&#B# GH;-64&B5*LN4&"B'K+D+#Y@,)!(0?;#)KJ.(XY3#]$B$3K,*3BE
MJRHG$'5F?R(+41B$),PI1D("OX E/NMN7\#3:8A-.,G-O\Y3:SCH/ZL-1FIQ
M/*1/9/!U.>/#OG(%0$]QN5C6&TT.7'JN0RUV4>A#,)Q#3C/5<QB@I$A-+R-J
M3O3%9$%L!\7$5WDM6:\C0S>4'SFB]6:F18JD2JG#9RIB,@I/&XUC]D)N2NC$
MVV!,5W.E@Q@%1*5"+BDJ!8A #TAI6M91,]]M"8.42(GG,]7@$C; !+!*:[IL
M0W75:>&B( CU/EP2:_0U=!UQ7O!/B-QK-H$)+>;_08QDHBHMJ]"0\@L2H:>8
M!HX^@]]6AAAO8'\*3CSFX?%.LT,Y=RZT[V,$;0.7;U(1H^7$3IB:+%&=9E'/
M::,TYQS1XMM@XF;F ]<4P[\@P/CZ%?_8Q;/FB4^"C6*;2C-DP@(H#3#B(P(\
MHP_)2";ZK# DJJ="RRK"*0>BD69 B!<OT$#8TK5JIBNRD4+W-8)P\-IV*3,P
MB1]%9707:%[**C%04.4$5-M$ (K$:00&TUI9!&&@ BQ]MF=2X!*\]1)B0UI2
MR4<W$S-3R;$2  0XX$:B\OT$;( "$7EM=&3[ G]%-X@WQ!O_0M%<MEV"0IX4
MXL4>)&.@JDGLXWXT)@U^_V,M+HJ) (1S:X)$:(1J?TIK&( E\HXF7$2Y #&$
MG$L "S%19%'^:()$$(!"*L+.O!, HBFJ4/#Z;N4F GB&V,(^-M$.6Z]!YZ&]
MO/,1T21^5:PX_F=0(( .'JD_'V8X$V. %,>ZPC#9OFR^^L/PH()L(FR*YN?P
M/)!QE"HA]V(B4F -F#%$N7*0)Q"X1A1'?(,"*LP.^S#QI'-*BJ@"1J!+<"KE
M"D![M8(&1ZQ" <"3H&4=6ZE<9T/SB!25H/EXVNUW-L .;,\W&$ P-J.2_9 _
MX'=18B^+2&A+A?B<B4+PQ".,FW<^0<M"!'9/)  P 9!HQ^T!'& J4(1;N"E^
MJ=6+U2KG>@H  S  .4-K::@U7)+C+EZD*?A)NTIFAV!/[YRB_RRU KH-H=("
M^33#NR9U;1:&?2WB71'Q*<34H4I"!+K-G1.8+Z2R([.G+>OJ/C#LE[3Y"AC%
M+<!&W!9@ ?X3 [C' 3'D ^"/5X'D0W2M0'"U+0/5@HFVV)SN5NM2WTPP9QYX
M)([5]N0S62>B@FO".?6T,$*.)//D*'*@AKJ9FI WEBU5 N8L2QYV(5#@")[%
M-@B+E9*'<8W,"=EM=U"8<KLGC"4  V!G>:EH93KE!C88(='_N;%]*BW20 ,L
M8/$JY(@S]2Q0I<9.QI[')8D>P!\FA',8@&!! LR8;7BWF'::-\MZSXXUHH(8
M)3H+HNM<9HMB)46*\D&H"7N:(FGAJ6HC(V8!NF$V0X<B1EO<]Q]W$"KJ DP*
M9ND86YA #2>0R(Q>HH-8Y";DT@49X -4)7M![&E0%>"DLXM)#@*5@K U<:(C
M"I39KH+B8G/Y VR,$9F1%0#N3E)CCY>6@FU;4T,XY)!0U&A4C$6#T',"HSG#
M,5=BRS\49ZI&8[0 P X^:7<^\]T4MW&5\+ Z;P7T +("6XIRL'4QB?5@9("
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M1 E*FMVQPA%'4S@%^'>#!'4^QX (%J@E\GL&82 <P"PN-IY#]M*%\5S>O*4
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MI5,"3L,2.V>GX,@G4TIC9K0E9:D=X)%M?!(<;B2%]M%Q0W:$._(>@"DG"(0
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MAP_H +((NBK[P-72+K+ D0Q<M 7(1-6ZPVD*#7ZP@F[PP*20D[1@B'P"KXT
M#KGY)YC@&9 H"<GBI'=Q"<NJOZ:8.%0:1-TZ"3K(* B!**7)L_::$ZL1_Y2.
M6Z1H_#&S^  L%$4!$[_R\PDB[( U09RP.)5M(:.,^)5V7  [R4"I02,:"[*+
M(!4JT2)UY)GZ.4A_-+UZ63;8R(Z3/(X*Z K4P8G86R VW)>(M+W#@)Z!W(S=
MNQ/KX*"DG$HB**$00Q(3@ =W:[<+<Z'HF[Z5,2F5.JE3I+X8:AE;?"'VL*FR
MZ\I@S$NM\S/00:(*X!NZF(O\@RH**;W7FKJC2IVD2J=(2Z-6<30XPS\0[ :^
M&B>^@:=;\<9OU,+SR(%Q=!+HZ;*+@ZW:R<?54)\11$3 \IH>@8%,6Y'+BJ_"
MVA-%(39CN\$;R)89ZY$7/+ 4XR@["X_8"PMFC/]-"TB#!.PDR&">)G$ 7HJ*
M H"&:8JT.$$*G+B=U9DRZ&B-J8A"K>F&#K@"+$R>3\/+]'@7WL*!"'&\7O,:
M:92ZU(2[N2@(I BO"D2@T9,ZYTS#LJBF'7G(>(*Z*=%.G'"G$!"U#<&Z?9(7
M@5"TJ[$4'"0+?T@E F*,Y!"8HM"OQ@(HZY@H']0MU3L)SC$!_" 9^5 $5QP0
M>*,W")NAM@09&*J/%?*8E\J'?E"#CFF/FT) O>S18(2=B,B!1QF*^=P?8,J+
M>V$<Q*$[O.@:7FLT+\L:S;")*84!<N2;/*B'-4@R$/5"CV(F$7"E-5E(^!M0
M:>2J7+J:N\-#;<FTO2C_S2]+"L)ZI*8+/<)Y*"MAFD6K"(*,I!#EI- 9G2A;
MH!\S& #ML^%+&WA)!&YH#H& !KZ;N/J#O3;Q#-D"-D"9D2EE1KVP @CH@'K0
MPP#"%:-)&Z!(A [H@&YPFUY;'_K<*AUIJM0:"TC)P-8JB-#<O?XLPQUQ@.Z*
M2'E2K%.ZG>?8+M3SKJFLT#7HH\:*LH(P-M/)C<XB//O:#N8(#IMP/3*EBM[#
M#@0%/@.##"(P@3J0CR[(!P[H!PZ0T0F[/N>CL'<]*0,ID.FCT1RJO@K;  X
MA"0)%Q_]5_,+,%.=G!&0(LO+,1I[K2?,BP:]P1O3"&CTSNO\C) 3,H*Y@2'!
M_PH(\( M/2_?_$: 80PVT F_B! T;8H@.R0\P9/,6]F\JIH.Q%@*F1!\#,S9
M7!@^))370YQO8YU$,4^J[!-08B?=B8F+L(!,D:Q^42: 64#$$%)PHHCF@%1T
MN2PJI:KVDE@$@K0R7,(7N0'*] =/Z<113=;:X$R'PX&(PPJ,O4/ VLCWQ)%@
MNYU_@I2FF)"\Z[@=N8PW8@EYXKAM02/R"L23@,@/_8EXZ;JB (ZV(M3?*"AJ
MK=:#BD@,E;&&FHJC@"B)*EQ>P1 2P (04+?Y0 %%(! )>S<(F]<6;2GF:RF0
MR:$$R <[R(<#V0 [2($/ EC=#48@A QP$ J^Z:NFN/]('3RCB>.U)]D\NW,5
MQ*RD) VC@8 !##B?.BT)BXE<0E34'/" )FG"A<V=4K&:A'!9E]4JX?*6"!G3
MWJD3@X# &V"(7L2?EQ"48*&D?*03R!()H/60A!R=M[D<L=BY+!J.UND0Y"$,
MQ*J'$7 >OG *Q"PSIYDF+%K3]N+.CI-/OOBF#X",LO40@TL!V6F]UJ*DZV3,
M-!I?A&A9ED4=,NLEH&/&\:*)KOTX!.*N#@I6Z* +%A8-? K9H#&@HI/AX1R8
M:)7*_>7+X)N@BL/*FZ2.#CU 1:VO$F*8AS"!?D"!#9@IDK&P :FP"%N9>JTW
M LDA".OBE;F$]E"$#< "W/W_T-U]8SK;#L\9.-X* ;]!3?T1+L#2(L4I4%CA
M2=N!DR KT&VYVL;"$@\ B7 Y8H,41 98@RO@!LSPEM98*DJC/_+%,TG)B[@+
ME>P4I@;52A/$V;^U7SN<LMY4L7ZEP3N#M/9IW&^AT TA@I#HB1RX @O BL"$
MS$KV*^)T216TV/9"TV*RT@\X#(O9WY[P))RIC#X"9OR+M#;A4SI)I"#99!V)
MPA$V"-=C/#%Z6-?X5;^=I$0;+$N*S>$X4*)Y%WZZ2=ZH%(+X$8/HP0[YH&P;
M& U=QP)5&$;A7'XA CO8 !0XF7I+W59TT115RQM-:'L5$ Y  3M8D!0X,3BN
MZ/-S_YT20JR^$)SCA9(RA)5(6Z?VG)$SN@&XH<.MH6"OX O 2(/8H.7BZT*A
M(3Z2H&6<D9*%!4 >&1C#.:!I=N"\S8@OL,=H" )K@12E6(W+@I2.*  (X,>T
MR9]B"9:E<H"!U)SD^=,FVKI08B@,0B,*T8GYZM*S,DB/<@@1$!W7;$\09%BQ
M*"V+..GEU=D'F) )D#6^4610VQ#%6 G.O!4A)4>]^S6,]!977<@B*[J#Z2M>
MNL>YBPX<61'ZN6'*F3H9<XUCQ2E)K WMF(W;D(XY!9[9,9V!<* IAD2S=8AY
M (_<XXW*,8@+>( -PA#.(3=-,4A=&5=VY>():]?H4]TNIO^AEI$'D^*WE-FA
M SF"$Z!HZ[5HYUZB -OK(8*,[2W9OQ*4R_KHNTHCI) )()L27MTQ%:0DFX"Q
MR\J1=:&+E;/M+EP.[.5<V0A1R"@!E[#4MPX/Q2N(!? 'NH 4N+/.W6!A8GE8
MTU,(?[B"-)B'(%@\QXPOJCLS/HF-25+#HCC2TB(636KDR8H6!G@4.7&1-C,U
MKR-@64ZO@66 M*Z'A,6XHK!@P*785RF=RZ+"C92Q*$212-4HELN0]QZ142V^
M1F&FQ,HS)04LIPI@1$+A@90EBAVGZ36;;2!-8BW>W.$NQK"8<8'6\S8MF)C#
M@=A8PX4@R$C<ZG$.+R\6C"AQ?2+_"6U#IR=9HZ(0'@WRT+>X2RHVCHDN@A_*
ML'JET=/]&!V2R[5,/I:1(7U[CTO0@Z\,<@U_;D<WOX80@;@PMHIX#I-3&LF3
MU%L=%7191^R>&X-IE6"2):EPN^LVIK+Q5A1[H(:H -#R%,)Y0I,+!UKGFD;B
M!_Y2M CX%?X)#:4IG12V)K'@AE"%C#1PL<M@G]" "M,R")JPTE\-/@"X O]=
M]J_J"%F*BKIFG1%0Y$6&;@QI"_-ANZ@P-. B+7O" /JY<Z%I"P:@ QR("RFZ
MC# RQZ +#UA)O&PW--_XMO;$*E%R;5$:' 1@BRST($1-^/,(0S6)NS(=&Z73
M1/K<B/"Z_QHE3^&#>,(O0%4($$D&;-_GJ/!]KY1[\0L)T,/%X!PT@ #HD25:
M/[FH2)'-ZF&  5J2X*@*6&#&"H<)0)'>X#*P@($10,Z/$IK'\(NUF@ZP<GE#
M"_KK>(RB42:0L@,TUH\9@M'[< \=6CZ7V:'EFP^OYZ%]$^B(?L3)?72T_\42
MD/2";0Y_OW>$]69.IY[(YC)K,D?"XB5*,1U#\XJ\(8\OX5&%HP!)_Q1_>$U$
MJZ,<X4@;F;2KL2=B@8%N&($\@ $VH(/$0*L2N1Z[T)_GL)2@YX;RB UP9(."
M[7P<IY,(2)%*(0I/F2]D9>2S]5L6TQF9E276-[0)N&LWD0 /Z/\H@_N<AEA[
M#2C&K  .QJ<=FZ.DMBOU'!N(E3R@AA0-5WUJ=N]Q#7D,-I#W<G%.>\*)07K5
M%I$?/'W\+M<?L9"0,RN.< P"8XR)>V]Q<^_Y;)4 .B@P[EB#K:"+MH(*@ A7
MX $!@@5@Y/'  ,!"  H 0(PH<:+$AQ 9,,AA 0*"&U\(AB-0D& $CS 00"C!
M, 7%EBX=2BP! <*7+]"ZW0@'4F>X"3!N0)"0@\++HA0M2B22PH0=#ALX7+JT
M0NH*$"ODR>N70.O6!%W4:%6S(L'8%2NTAC5["04'/518&HTK=R[=NG;OXLVK
M5R)<AA$S?D @V.,7!%]@//CX,<(7QHG_&S<N"9DQX\8W(CQX@-CRQ\P?^74L
M+'B$AJ$+&^Y-_9>AB"L08/CS2/@RO\L$"@Q\@+O [8$%:M:\(1L!#"F8/(B8
MY_<B@R C!$,@7/.![)H()(P(@A% BH=PU]2# :.DR((W-#^8\,#*#1@C/)18
M2 0B4M4M43-D\_KG9<R)!XKT0$DP6'!%0_.EUI=$VV%4@08AU(/ "-P(5A-'
M@AD6VF&)4?>%<,%YE)ATU3%&6&W C2 " PC*5=]<#,PC0@@2<.-/30Z<)^!E
MDWUQ(C\]>C@==27=4(!PA"% H0<5,)C1)QWAYID#C140 0%'PB!!(A@MA%0)
M$H174CA6>NC17$TF25',=JEY Q$%&%UA@3\P..! >@(.]&%A'1C8I5XL6;30
M!YCX8UB)5 9HQ6%:4D"4:OCQE0(16.CQU"58R7-)/VI199:G\DR%E512@<HI
M!_U\8P)<"MK7JJNO_\(::U'UL<0EC"6PX=H(%L!PH89!$ADD</\IUB&P'\YV
M@P."^<.1!!!<P49\##DJZUV.$I61!A%BA\"</^F&6Y$1&'G;#5<:&5RA*#V+
M0P5O;M<FER5\((&WOD:W;J'-?I##<A8YJ@$F(W03I&P8''F8>Q: <U%%LC[T
MD*TEA##"<=3Q9_!',&#002(YL+H74FW^U20#)>3 Q@=7>$ @!(E T#*WSW7P
M7(;!.6:PC\$%5]N/#Q@V0@AT+">RFRR>=G)K&%0(0YG3I4L=/R51!IF'/YO4
MZW40N-LD0PQH$)J1RPI+F'C7B1#10RP&T4$'3O,<)(XH81*"2@]S1Y=%\_^=
M)H(%&_U4IIZ'<52/BJBQ*%?( !!Q,LP(="/!#;$!=P,_W5PG0<.+ZS4?K2E(
MRA0'3G%::E13J84Z55&=;JD>)I"@8.+6TEZ[[;?CK8#N$G^]9@[@7%%/4*\5
MJJ>('FI68G7(5EY3X)-WE.5&T>; (%_5XBY70X"% ($%W1XI[@6:76#DA\O:
M^ZP'R!%=M *G]?Z!!Q8@(/Q&],\4E <:S ._VA&5X H8P 2&7N,]XD!' A;X
M@/\<@CU9(:@A.?" S>;$K'QA:",J@LCL5 .7!V[/5MN)3WPH4((25$ $N4I$
M/?XF&/$()S,1B,"/^ $:RNG,0^' $0PPH8$UP83_/K%"H?P0L"S94$=$OQF1
MP0[EH=%8(!%H\!< X$6?T[B&/>)Y#710(IAG:8!:%,&(!H*"DB]P)'^)$(P4
M#%=%2.7E?<OY  0(>*$MHF0$-8/ !AT5,;WP#@ BJ,<([)6_Z!CF!A+H  30
M $19X8<EH*,"%NQP":=L0"K]V&0_.H&535Y%+4^!R@E,H!3023)[JEPE*P$I
M1*0$JG%%HT *5+@^7T4/1T_34W4*,[D;>/$DAD2)!T)0C!S(TF&T1(V+6@D1
M296,.70 A_Q"<#8)8=-FV!1,/3R @P^(0"7;B]A\D'8:"N1@#3E8)SO960%Q
M_JL[\TG!0B@@@L=)()\*_X1 (;WG 7 T\'9M0LIV<E!&[Q7R;_I\%@1*X[ @
MPDH!(8,4EU:#$4<Q@ )K )[P1G ####M!CB!# +X0;GE\4- P1D!!*B(-XCB
MY8\A)*('OB"!N7TH- @+' :^@(&?C(:8'P!H2Q1 A+5AA W=NX$>$ZK/F=2#
M#>=TR-[ZY@$$?"^KW\..!1SZTKMXKB%O D %@K>KH$C@27^KAP8.QP"6##2.
M$B$:8.JQT,SELZ$B( HM:??(O*&2"%0PP3?L8(=,;: 6*]B 63)IAWX8%@NF
ME.2J(N*-!SHSLYK=[.Z\<=2'N@2=(O@ #M;7,0E@()]>9&D7OUC(9UVGF%?X
M /\;<J"2; 64/I_=K!"?&1%Z3N1-.:B RCY@W ]HX+C&K6T:^N>7!NXN(D3
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MS1% 2BG&>?"&1"I$?A'F<OY%A.@,B02)CE@'&]!'C]Z8?J9JL1KKL2+KF#(
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M30S0[!8(3Q;#3T*BPV)/(31C?Z $4+JM>FP.9GJE9_KC:_2@.^S-?18"04!
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M!A^_#]-<A9BPT!OM0#UD[XPZR>]B8RH9 \[,)N1$(I=FPVI.XVA(0#.Z8,[
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AW=5?'=9C7=9GG=9KW=9O'==S7==WG==[W==_/7 " @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">501 Canal Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sgmo-20250807.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="sgmo-20250807.htm">sgmo-20250807.htm</File>
    <File>sgmo-20250807.xsd</File>
    <File>sgmo-20250807_lab.xml</File>
    <File>sgmo-20250807_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sgmo-20250807.htm": {
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20250807",
   "dts": {
    "inline": {
     "local": [
      "sgmo-20250807.htm"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20250807.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20250807_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20250807_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.sangamo.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20250807.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20250807.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-25-038855-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-038855-xbrl.zip
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M!,T##U H,<"4 /@!O@@O R]@WP$D@IFO7C;;QW5$.C!*BG1K%'CP)7-%''B
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M,C"&6>T<M-CX,U$5^/#TMUEM-\9U^N=4\("][K3^"PP_=R !-Q;:<B#W@.;
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ME13;43-YW<@XH0?5+0;+[YCC 4(8ME&V0"!$20=4_ H;#P4P91S@3-B04>T
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MF@<@5+EN,HC\C\9!UHN,R-I)4:L-(>'B:+BU=/K<!;&PRJ$7R5R'N?SXRK9
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MY6L7\TES^98^T'YN>"? (*\%$FI?.X7&R8!@OW$R) (CV5\C/Q)Z<UIH1J$
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M]LG$>DA#;4"D]79*U5@<WU)?#!P@T3\*JEWCA,<8!,)EDF/IYW20A:&D1=,
M:(8]X?!D.,1L? S_]&$*$<5.&8:72&DXH/W0\8#*A!72"?(QO"B(F/.KH?X<
M]X *6@\/:3!VWG7I$$3QDMRB=C3$X;LC#B3KI6TX_1]QS#I,H!YO4X1J,(2T
M;#F"*59?+UO=\P^HTSWKGG?F49I!9@< [9PWO[9;W=9Y!YU=?D#G?S1_/[O\
M=(Z:5Q<7K4ZG=76Y'>BME:#_AOD 7 P1A4?H@][4P3FHE.T%B#<(EW$'KO)2
MN'[[U:P:Q]NAW$8@G-$H-> .2.K'J_8%6GU=REW,=)5.ER4P3G7M\]TU">WE
MY77)RVJV >Q:^_RRB]KGUU?M[BY;L>N$\01#-"0BU"&>=,-3<ILE%#%D5@[\
MPUV&/^JIT U 3Q@5%,8\'WD#<.4(.O,$@M>F72J_)MF17I.$NTWBB ETD#\3
M#'X3X0*1&QF],O6:^(?.$PS3M7+&SE,7K8#2" Q<K)%P?/A&&\(0 ]E-\_%8
M&\/4&@DG#G:A<9;T$RY20:D=J;!XT=O^BR1?YI+M[>/C$&YJ<JN\DKBN&Q*V
M29]R&?>+2WB3RU0)O$'P_<XNKE#W]_/VV?7YUVZKV3E"K<NF?I]HO3"9%]?J
MK<C <C8<G(\@*E'4EL:"3:B,,$<\)IX, 'U$0T0%1V AP7:P1<N^)=F=EV"!
MW8#D,+@1@V!0 U "''/BY!^.\WQ%FMS15*<\&G,C(:*A4P$0;@@3U,-!QA_%
MJO1U%@K:MEXS:E*2!<2<PL\GS@)%': L+GY?,O1*S5SZRM#7^][2+=M:J\?K
M ZK\X%!%17F6O\P%!-A74)V YU(R3@NE0MXFQKY,\#H&,J%5<;>;9?@]UMZ*
M1[+'XHJX(,11_/(69EU#WPJ]B(&/HE*['0%N13-*0L'&S<B?]SED7D6FE@2)
M670CQYDZ&V5PB$B ;S%;DL_+C)?PGT#9@/06C$-J%[:]@#\-GU<L*1]I0*"Q
M"^MFQO6*RF-J)<.LF7NV_Z1L[^)1*TM->\I(S,M M="HUC6C5+$KE>J#0K!I
M\[IQ>5@MR72@C*2,NB,(:1GZ$R):[E,5DX-/I\(A.FM4#U^!*MQ%_:4U85N\
M;$;#(>5R2UKQ39HXE,KWGFN[R[56NX/.AW$0C0E3?&M]6,HU97&**N38=E+I
M>6SSF>\SPGGVWQ<8S\SM<JW0J!@F:N(0!^A]<.,OQ.=':V2DYJ9KPL<KUHUN
M)^Y?O=!H4V\PC$)_8[,H,WO%KL'7I&KW?457U"XTFL!%:!U2O)C(?QHPUQ',
M%OR'QJE7G.T5&(6&7:X;Y963:L\I8BOJ3H:0S#[$# A+8Y /,B)>(NB-3$K
M,D_X(3H 9)'$]OZ\\@XJT,'J_)52?,8(GN.H"5IC&G?Y>;B&V'R)P#Y>#Z+P
MCJ]L6B L-4.K NZ/;R_MD,!,,X&__5JWS-HQ1X($))8HHE#A>(1 D()$+AX(
M(D ,] &YV:7]H-6DYS(2Z"R. UCB8,G89:9\!%L(ON>ERB,RE#UFN@WLZ*&F
MVEWQ44<:3_0%<Y%M5=S'EVW'53N;L6\.B/==;5_A&)8;L)K2_W>C$7))$-U*
M8LN7D@>HKGU&/1I(1: <M$*0T <FB AQ.DP"@4,2)3P8(PZA >^-5<^L0^0"
MLC@+(]2+F?1P N,PA,-Q_JX7!3"Y[">70"I=6.[L&E-?/$5<KY3631%7]%I]
MO:3K?2/9EFZ8]BHIU T%%&OE#\Y ;@/T-:32.*.+#K 8AUQ[(I]77Q"_,2I
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M5C=":L3?9?:;8UQIPJEI;C^^E:!$.U4<I=@_['G8FG"<X#0>[E0>A/]0PV'
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M%O8W;?__8AN=8;_BR\$S4$L#!!0    ( %R !UO5\]+]) H  'A5   5
M<V=M;RTR,#(U,#@P-U]L86(N>&ULQ9QO;YM*%L;?]U.PWC>[TIV888:!J=I<
M=7/;JVASVZA)=:]VM;*&^9.@8H@P:9)OOP.V$X@!,X--^Z)Q[/%YSG/"S^>
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MGC+M1^\PYLWXL_-M!.%^6U8D]H2=#,?]UNI,#EAM#N8''4J4X3XE[&81ACA
MW"/ +9L?=@D&(6.Z^?DP"F#D$R+X4!8;D8^,W[.64XH-YZWI?C]BUI[,J!IH
MQPBCUM2MR&E&F@R65@-U/MH7F"/Q,2WBXNE,!\I9<JXA>_RW?%IX'+H># ,0
M" 8!+K^"I:[N56X8<(85"Y _^!!XJ\*1$5EK.AM1IU)UM.QP6-KKLA^:T6[-
MX#$V:H11KQDKG-HC3H95KZ$Z7OT+1X^$YZO5O<SK$P^"H1*\_*8,(:D'0Z4
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M>_<'^H_^Q?BCO?\!4$L! A0#%     @ 7( '6XY[;]E:*@  Y9H! !4
M         ( !     &5X:&EB:70M.3DQ,#@P-S(U+FAT;5!+ 0(4 Q0    (
M %R !UME5F(E[0\  (R!   1              "  8TJ  !S9VUO+3(P,C4P
M.# W+FAT;5!+ 0(4 Q0    ( %R !UN;R6Q^8P(   ,'   1
M  "  :DZ  !S9VUO+3(P,C4P.# W+GAS9%!+ 0(4 Q0    ( %R !UO5\]+]
M) H  'A5   5              "  3L]  !S9VUO+3(P,C4P.# W7VQA8BYX
M;6Q02P$"% ,4    " !<@ =;R#X&&:T&  #H,   %0              @ &2
M1P  <V=M;RTR,#(U,#@P-U]P<F4N>&UL4$L%!@     %  4 1P$  ').
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>sgmo-20250807_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgmo-20250807.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-08-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001001233</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30171</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">501 Canal Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">970-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
